PI
NXTC icon

Putnam Investments’s NextCure NXTC Stock Holding History

Putnam Investments’s Portfolio NXTC Stock Details NXTC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-7,192
Closed -$4.86M – 897
2019
Q4 		$4.86M Buy
7,192
+5,034
+233% +$2.53M 0.01% 511
2019
Q3 		$799K Buy
+2,158
New +$702K ﹤0.01% 776

Other funds holding NXTC

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
CPX
Canaan Partners X Menlo Park, California $74.7M AUM 151.56% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

Putnam Investments's NXTC Position: Q1 2020 in Review

Putnam Investments sold out of NextCure (NXTC) in Q1 2020, closing a stake of 7,192 shares — an estimated $4.86M sold.

Putnam Investments first reported a position in NXTC in Q3 2019 and held it in 2 quarters. The position peaked at $4.86M in Q4 2019. 82 funds tracked by Wall St. Rank hold NXTC as of Q1 2020.

  • Putnam Investments reported no remaining NextCure position as of Q1 2020 after selling out during the quarter.
  • Putnam Investments sold 7,192 NextCure shares in Q1 2020, an estimated $4.86M.
  • Putnam Investments first reported a position in NextCure in Q3 2019 and held it in 2 quarters.
  • Putnam Investments's NextCure position peaked at $4.86M in Q4 2019.
  • 82 funds tracked by Wall St. Rank held NextCure as of Q1 2020.

Based on Putnam Investments's 13F filing for Q1 2020, filed 15 May 2020.